Latest Insider Transactions at Pyxis Oncology, Inc. (PYXS)
This section provides a real-time view of insider transactions for Pyxis Oncology, Inc. (PYXS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pyxis Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pyxis Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
306,930
+46.67%
|
-
|
|
Mar 31
2022
|
John L Flavin |
BUY
Grant, award, or other acquisition
|
Direct |
66,831
+21.89%
|
-
|
|
Dec 08
2021
|
Darren S Cline |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$90,000
$9.39 P/Share
|
|
Nov 18
2021
|
Thomas Civik |
BUY
Open market or private purchase
|
Indirect |
15,700
+50.0%
|
$188,400
$12.74 P/Share
|
|
Oct 13
2021
|
World Investments B.V. Bayer |
BUY
Conversion of derivative security
|
Direct |
2,742,338
+50.0%
|
-
|
|
Oct 13
2021
|
John L Flavin |
BUY
Conversion of derivative security
|
Direct |
2,388
+1.37%
|
-
|
|
Oct 13
2021
|
Mark Chin |
BUY
Open market or private purchase
|
Indirect |
312,500
+15.18%
|
$5,000,000
$16.0 P/Share
|
|
Oct 13
2021
|
Mark Chin |
BUY
Conversion of derivative security
|
Indirect |
1,433,261
+50.0%
|
-
|
|
Oct 13
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
450,000
+28.68%
|
$7,200,000
$16.0 P/Share
|
|
Oct 13
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
668,854
+50.0%
|
-
|
|
Oct 07
2021
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|